Sandbox Reserved 1736
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==Structure== | ==Structure== | ||
<StructureSection load='7qus' size='350' side='right' caption='C3 symmetry of SARS-CoV-2 spike protein' scene=''> | <StructureSection load='7qus' size='350' side='right' caption='C3 symmetry of SARS-CoV-2 spike protein' scene=''> | ||
- | ==SARS-CoV-2 Spike Protein== | ||
- | The SARS-CoV-2 spike protein (Severe acute respiratory syndrome coronavirus 2) is a protein that has emerged from the COVID-19 virus beginning in December 2019. Both the S1 and S2 subunits are the last two regions that manage the processes of the receptor binding and the membrane fusing. <ref>Berger, I.; Schaffitzel, C. The Sars-COV-2 Spike Protein: Balancing Stability and Infectivity. Cell Research 2020, 30 (12), 1059–1060.</ref> | ||
- | In the S1 subunit, it is composed of an N-terminal, receptor-binding domain, and the fusion of peptides, heptapeptide 1 and 2, TM domain, and cytoplasmic domain fusion are the reason for viral fusion and entry. In the S2 subunit, the S-protein trimers have a shape of a crown-like looking halo that is on the surrounding area of the viral particle. Because of the structure of the coronavirus S protein monomers this causes both the S1 and S2 subunits to be formulated into a “bulbous head and stalk region”. In the native state– the protein is folded to be able to operate and function properly. In this case the SARS-CoV-2 spike protein begins to exist as an inactive precursor when in this specific state. However, in a viral infection state SARS-CoV-2 spike protein the target cell's proteases will activate the S-protein which is being cleaved into both the S1 and S2 subunits. As a result, this allows for the activation of the membrane fusion after the result of viral entry are in the targeted cells.<ref name="huang">Huang, Y.; Yang, C.; Xu, X.-feng; Xu, W.; Liu, S.-wen. Structural and Functional Properties of SARS-COV-2 Spike Protein: Potential Antivirus Drug Development for Covid-19. Acta Pharmacologica Sinica '''2020''', 41 (9), 1141–1149.</ref> | ||
== Function == | == Function == | ||
The SARS-CoV-2 spike protein helps extract antibodies that neutralize viruses into the body. To enter a cell and start an infection, the spike protein in SARS-CoV-2 (SARS-2-S) interacts with the human ACE2 receptor. The ACE2 (Angiotensin-converting enzyme 2) is an enzyme that can be found in the membrane of cells in the following: intestines, kidney, testis, gallbladder, and heart. The SARS-2-S is split into S1 and S2 subunits, with S1 functioning as the receptor-binding component and S2 as the membrane-fusion subunit.<ref>Xia, X. Domains and Functions of Spike Protein in SARS-COV-2 in the Context of Vaccine Design. Viruses '''2021''', 13(1).</ref> | The SARS-CoV-2 spike protein helps extract antibodies that neutralize viruses into the body. To enter a cell and start an infection, the spike protein in SARS-CoV-2 (SARS-2-S) interacts with the human ACE2 receptor. The ACE2 (Angiotensin-converting enzyme 2) is an enzyme that can be found in the membrane of cells in the following: intestines, kidney, testis, gallbladder, and heart. The SARS-2-S is split into S1 and S2 subunits, with S1 functioning as the receptor-binding component and S2 as the membrane-fusion subunit.<ref>Xia, X. Domains and Functions of Spike Protein in SARS-COV-2 in the Context of Vaccine Design. Viruses '''2021''', 13(1).</ref> |
Revision as of 19:23, 8 December 2022
Structure
|
References
- ↑ Xia, X. Domains and Functions of Spike Protein in SARS-COV-2 in the Context of Vaccine Design. Viruses 2021, 13(1).
- ↑ 2.0 2.1 Bangaru, S.; Ozorowski, G.; Turner, H. L.; Antanasijevic, A.; Huang, D.; Wang, X.; Torres, J. L.; Diedrich, J. K.; Tian, J.-H.; Portnoff, A. D.; Patel, N.; Massare, M. J.; Yates, J. R.; Nemazee, D.; Paulson, J. C.; Glenn, G.; Smith, G.; Ward, A. B. Structural Analysis of Full-Length SARS-COV-2 Spike Protein from an Advanced Vaccine Candidate. Science 2020, 370 (6520), 1089–1094.
- ↑ Suzuki, Y. J.; Gychka, S. G. SARS-COV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of Covid-19 Vaccines. Vaccines 2021, 9 (1), 36.
- ↑ Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J. C. C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H.-H.; Michailidis, E.; Gaebler, C.; Agudelo, M.; Cho, A.; Wang, Z.; Gazumyan, A.; Cipolla, M.; Luchsinger, L.; Hillyer, C. D.; Caskey, M.; Robbiani, D. F.; Rice, C. M.; Nussenzweig, M. C.; Hatziioannou, T.; Bieniasz, P. D. Escape from Neutralizing Antibodies by SARS-COV-2 Spike Protein Variants. eLife 2020, 9.
- ↑ Jackson, C. B.; Zhang, L.; Farzan, M.; Choe, H. Functional Importance of the D614G Mutation in the SARS-COV-2 Spike Protein. Biochemical and Biophysical Research Communications 2021, 538, 108–115.
- ↑ Guruprasad, L. Human Sars-CoV‐2 Spike Protein Mutations. Proteins: Structure, Function, and Bioinformatics 2021, 89 (5), 569–576.
- ↑ Berger, I.; Schaffitzel, C. The Sars-COV-2 Spike Protein: Balancing Stability and Infectivity. Cell Research 2020, 30 (12), 1059–1060.
- ↑ 8.0 8.1 Huang, Y.; Yang, C.; Xu, X.-feng; Xu, W.; Liu, S.-wen. Structural and Functional Properties of SARS-COV-2 Spike Protein: Potential Antivirus Drug Development for Covid-19. Acta Pharmacologica Sinica 2020, 41 (9), 1141–1149.
- ↑ Zhou, T.; Tsybovsky, Y.; Gorman, J.; Rapp, M.; Cerutti, G.; Chuang, G.-Y.; Katsamba, P. S.; Sampson, J. M.; Schön, A.; Bimela, J.; Boyington, J. C.; Nazzari, A.; Olia, A. S.; Shi, W.; Sastry, M.; Stephens, T.; Stuckey, J.; Teng, I.-T.; Wang, P.; Wang, S.; Zhang, B.; Friesner, R. A.; Ho, D. D.; Mascola, J. R.; Shapiro, L.; Kwong, P. D. Cryo-EM Structures of SARS-COV-2 Spike without and with Ace2 Reveal a Ph-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host & Microbe 2020, 28 (6).